Thinking of investing in these Neil Woodford FTSE 250 stocks? Read this first

G A Chester discusses Neil Woodford’s FTSE 250 (INDEXFTSE:MCX) investment trust, and a mid-cap he’s also heavily invested in.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m looking at two stocks in the FTSE 250 index. Woodford Patient Capital Trust (LSE: WPCT), which is managed by Neil Woodford, and IP Group (LSE: IPO), a company in which he has a 19% stake.

Launched in April 2015, Patient Capital is a growth-focused investment trust that invests largely in early-stage and early-growth businesses. It has steadily ramped up its exposure to unquoted companies.

Today, its make-up is not dissimilar to that of IP Group, which is an incubator of potentially “world-changing” life sciences and technology businesses. Indeed, as well as owning shares in IP, Woodford is a fellow cornerstone investor in quite a number of its investee companies.

Discount prices

Tangible net asset value (TNAV) is the appropriate measure to look at for investment trusts and investment companies like Patient Capital and IP. Currently, the shares of both are trading at a discount to their last reported TNAVs, and so appear to offer good value.

As I’m writing, Patient Capital’s share price is 84.6p — a 12.2% discount to its TNAV per share of 96.35p. IP’s share price is 103.6p — a 15.5% discount to its 122.6p a share TNAV. However, I’m not convinced these discounts are wide enough to offer investors a sufficient margin of safety. Here’s why.

High paper values

Around this time last year, I drew readers’ attention to a controversial report on IP by US short-seller J Capital Research (JCap). The report suggested that a relatively small number of cornerstone investors, who set the valuations of IP’s unquoted companies, had “a collusive interest creating high paper values.” JCap put a value on IP that was a 40% discount to the group’s accounting TNAV.

By way of testing this in a small way, I’ve searched out IP investee companies that have floated on the stock market to see what happened to their valuations when they were subjected to scrutiny and assessment by a much wider pool of investors.

I found five unquoted companies in which IP is a cornerstone investor that came to market via an initial public offering (IPO) in the last five years. The table below summarises my findings.

  Flotation date IPO market cap Current market cap IPO share price Current share price Market cap increase / (decrease) Share price increase / (decrease)
Applied Graphene Materials 20/11/13 £26.2m £13.8m 155p 28p (47.3%) (81.9%)
Xeros Technology 24/3/14 £80m £41.4m 123p 16.1p (48.3%) (86.9%)
MedaPhor (renamed Intelligent Ultrasound) 27/8/14 £10.1m £11.9m 50p 7.6p 17.8% (84.8%)
Diurnal 24/12/15 £75.2m £19.7m 144p 32p (73.8%) (77.8%)
Mirriad Advertising 19/12/17 £63.2m £16.6m 62p 15.75p (73.7%) (74.6%)

The average current value (market cap) of the companies is 45% below their average value at IPO. On a per share basis, the picture is even worse, with an average decline in value of 81%, due to dilution via further fundraisings.

I think this provides some support for JCap’s view that IP’s unquoted investee companies go in its books at over-rosy valuations. Of course, with Woodford being another cornerstone investor in this area of the market — not infrequently alongside IP — much the same criticism can be levelled at Patient Capital.

On balance, I’m inclined to avoid these two stocks at their current prices. I’d want much bigger discounts to TNAV than Patient Capital’s 12.2% and IP’s 15.5% to feel I was getting value for money and a margin of safety.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Labour winning the general election would be positive for UK stocks, says JP Morgan

One mega-bank thinks certain UK stocks could benefit following the 4 July election. This writer considers a FTSE share that…

Read more »

Older couple walking in park
Investing Articles

No savings at 40? Here’s how I’d aim to retire comfortably with FTSE 100 stocks

It's never too late to begin investing in FTSE 100 stocks for retirement. Royston Wild reveals three steps to help…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Down 17%, is National Grid’s share price a FTSE 100 bargain?

National Grid's share price has taken a battering following a multi-billion-pound rights issue and dividend rebasement. Is it now too…

Read more »

Environmental technology concept
Investing Articles

Up 150% this year! Can NVIDIA stock keep on soaring?

Christopher Ruane explains why NVIDIA stock has soared over 150% already this year, where it might be going -- and…

Read more »

Investing Articles

Down 44% in a year, here’s why the Aston Martin share price could keep struggling

Not only has the Aston Martin share price collapsed in recent years, our writer sees its current business performance as…

Read more »

Investing Articles

I’m considering these 2 high-growth stocks to buy as a technology investor

Our author thinks Kainos and Softcat could be two of Britain's best tech investments. He thinks the risks in the…

Read more »

Abstract 3d arrows with rocket
Investing Articles

A once-in-a-decade opportunity to buy these FTSE 100 growth shares before they rocket?

Our writer highlights two FTSE 100 growth stocks he thinks could seriously outperform as interest rates are cut and economic…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing For Beginners

Down 14% in a month, is this the FTSE 100’s biggest bargain right now?

Jon Smith mulls over whether he should buy one of the worst-performing FTSE 100 stocks based on it being an…

Read more »